MindMed secures Zydis oral tablet technology for LSD-based anxiety treatment
Click Here to Manage Email Alerts
Key takeaways:
- MindMed will use Catalent’s Zydis orally disintegrating tablet technology for the development of MM-120, an LSD-based anxiety treatment.
- MM-120 is now in a phase 2b trial, with topline data expected this year.
Mind Medicine Inc. has announced an agreement with Catalent to use its Zydis orally disintegrating tablet technology for development of a new psychedelic-based anxiety treatment, according to a company press release.
Mind Medicine, also known as MindMed, secured the licensing agreement to integrate Catalent’s proprietary Zydis technology for orally disintegrating tablets (ODTs) with MindMed’s forthcoming product, MM-120 — a “pharmaceutically optimized form” of lysergide, otherwise known as lysergic acid diethylamide (LSD).
MM-120 (lysergide D-tartrate) is currently being evaluated in a phase 2b clinical trial for treatment of generalized anxiety disorder, and topline data are expected in the fourth quarter of 2023.
MindMed CEO and director Robert Barrow said in the release that Zydis ODT delivery “could ultimately culminate in a shorter treatment session for MM-120,” calling the combination “an optimized pharmaceutical product.” He added that MM-120 is expected to “benefit from numerous patents,” the first of which expires in 2042, based on MindMed’s current and ongoing applications incorporating Zydis.
The release describes Zydis as a “unique, freeze-dried, oral solid dosage form” that almost instantly disperses in the mouth with no need for water, adding that its advantages include convenience and improved patient compliance and adherence.
The licensing agreement also gives MindMed exclusive rights to use Zydis to develop all salt and polymorphic forms of lysergide in territories including the U.S., U.K. and European Union.
Calling Zydis “very versatile and effective in developing easy-to-administer dose forms for innovators,” Tom Hawkeswood, president and division head of pharma product delivery at Catalent, said the company is looking forward to “working with MindMed in the development of this potentially life-changing new product candidate.”